Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 3 results

ea0070oc1.2 | Adrenal and Cardiovascular Endocrinology | ECE2020

A Phase III randomized, controlled trial of a modified-release hydrocortisone formulation in the treatment of classic congenital adrenal hyperplasia

Merke Deborah , Mallappa Ashwini , Arlt Wiebke , de la Perriere Aude Brac , Hirschberg Linden Angelica , Juul Anders , Newell-Price John , Perry Colin , Prete Alessandro , Rees Aled , Reisch Nicole , Stikkelbroeck Nike , Touraine Phillippe , Matlby Kerry , Treasure Peter , Porter John , Ross Richard

Background: Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD-CAH) have poor health outcomes due to failure of currently available glucocorticoid preparations to control adrenocorticotropic hormone-driven androgen excess. We investigated whether modified-release hydrocortisone (MR-HC), which mimics the physiological circadian cortisol rhythm, could improve androgen control.Methods: 122 patients with 21-OHD-CAH ...
0 shares

ea0099rc3.1 | Rapid Communications 3: Adrenal and Cardiovascular Endocrinology | Part I | ECE2024

Biochemical control with dose reduction in chronic glucocorticoid therapy over 4 years: A phase III extension study of Chronocort (Efmody) in the treatment of Congenital Adrenal Hyperplasia (CAH)

John M. Ross Richard , Merke Deborah P. , Arlt Wiebke , De La Perriere Aude Brac , Hirschberg Angelica , Newell-Price John D.C. , Prete Alessandro , Rees Aled , Reisch Nicole , Quinkler Marcus , Touraine Philippe A. , Maltby Kerry , Quirke Jo , Aslam Naila , Coope Helen , Porter John

Background: Management of CAH involves replacing cortisol deficiency and reducing raised adrenal androgens, however the supraphysiological glucocorticoid doses often required to treat hyperandrogenism are associated with poor long-term health outcomes. Modified-release hydrocortisone (MRHC) capsules, Efmody, replicate cortisol diurnal rhythm and improve control of CAH compared to standard glucocorticoid therapy. Here we report changes in glucocorticoid daily dose and 9am 17-hy...
0 shares

ea0077ec1.3 | Clinical Endocrinology Trust Best Abstract Clinical | SFEBES2021

Phase 3 and extension study of modified-release hydrocortisone in the treatment of congenital adrenal hyperplasia

Merke Deborah P , Mallappa Ashwini , Arlt Wiebke , De La Perriere Aude Brac , Hirschberg Angelica Linden , Juul Anders , Newell-Price John D C , Perry Colin Graham , Prete Alessandro , Rees Aled , Reisch Nicole , Stikkelbroeck Monica , Touraine Philippe A , Lewis Alexander , Maltby Kerry , Treasure Peter , Porter John , Ross Richard John M

Background: Patients with congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency have poor health outcomes. We compared disease control in CAH adults treated with modified release hydrocortisone (MRHC, Chronocort®, Diurnal Ltd) versus standard glucocorticoid (GC).Methods: 6-month, Phase 3 study in 122 patients randomised to either MRHC twice daily or standard GC followed by safety extension study on MRHC. Patients had 24-hr 17...
1 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more